ONC-392/BNT316 Elicits Clinical Activity in Checkpoint Inhib

ONC-392/BNT316 demonstrated early signs of antitumor activity and manageable safety in patients with metastatic, PD-(L)1–resistant non–small cell lung cancer.

Related Keywords

, Pan Zheng , Ohio State University Comprehensive Cancer Center , Onc 392 Bnt316 , Patients With Metastatic , Dl 1 Resistant Non Small Cell Lung Cancer , Preserve 001 Trial , Nct04140526 , Kai He , D , Phd , The Ohio State University Comprehensive Cancer Center , Professor Özlem Türeci ,